GleamWall
中文EN

QUIT ACHIEVE LIFE SCIENCES, INC.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 949858 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-113.4%
TTM EPS YoY-4.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-104.2%
ROA-86.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio10.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-52.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense—$22.82M
SG&A expense—$16.25M
Interest expense$819,000$2.18M
Pretax income-$54.65M-$39.83M
Net income-$54.65M-$39.83M
EPS (basic)-1.25-1.24
EPS (diluted)-1.25-1.24
Weighted avg. shares (diluted)43.59M32.07M
Balance sheet
Cash & equivalents$20.93M$12.75M
Short-term investments$15.47M$21.61M
Current assets$39.89M$36.47M
PP&E, net$3,000$8,000
Goodwill$1.03M$1.03M
Intangibles$751,000$974,000
Total assets$41.79M$38.63M
Current liabilities$9.08M$6.68M
Total liabilities$20.27M$17.73M
Shareholders' equity$21.52M$20.90M
Shares outstanding53.23M34.69M
Cash flow statement
Operating cash flow-$49.47M-$29.77M
Capital expenditure$3,000—
Free cash flow-$49.47M—
Investing cash flow$6.11M-$21.58M
Financing cash flow$51.53M$48.53M
Depreciation & amortization$228,000$229,000
Stock-based compensation$8.76M$5.33M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.